Table 1 Utility values for model patient’s outcomes and health state probabilities in the model
Parameters | Base case (Range for one-way sensitivity analysis) | Distribution type for PSA | Reference |
|---|---|---|---|
Utility weight | |||
Complete control | 0.827 (0.816 ~ 0.837) | Beta (Mean = 0.827, SE = 0.006) | [22] |
Incomplete control | 0.605 (0.454 ~ 0.756) | Beta (Mean = 0.222, SE = 0.077) | [22] |
Disutility due to drowsiness | 0.090 (0.050 ~ 0.120) | Beta (Mean = 0.090, SE = 20% of base case) | [23] |
Probabilities | |||
Complete control in acute phase in olanzapine regimen | 0.941 (0.911 ~ 0.963) | Beta (α = 333, ß = 21) | [8] |
Complete control in acute phase in non-olanzapine regimen | 0.880 (0.842 ~ 0.912) | Beta (α = 309, ß = 42) | [8] |
Complete control in delayed phase in olanzapine regimen | 0.780 (0.733 ~ 0.822) | Beta (α = 276, ß = 78) | [8] |
Complete control in delayed phase in non-olanzapine regimen | 0.635 (0.583 ~ 0.686) | Beta (α = 223, ß = 128) | [8] |
Drowsiness in olanzapine regimen | 0.430 (0.380 ~ 0.480) | Beta (α = 153, ß = 202) | [8] |
Drowsiness in non-olanzapine regimen | 0.330 (0.280 ~ 0.380) | Beta (α = 116, ß = 235) | [8] |